$1.12
-0.08[-6.67%]
At close: Apr 19
$1.12
0[0.00%]
After Hours: 7:53PM EDT
Passage Bio
(NASDAQ:PASG)Passage Bio Stock (NASDAQ:PASG), Analyst Ratings, Price Targets, Predictions
Passage Bio Inc has a consensus price target of $9.38, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, Raymond James, and Chardan Capital on March 5, 2024, November 14, 2023, and August 8, 2023. With an average price target of $9.33 between Canaccord Genuity, Raymond James, and Chardan Capital, there's an implied 733.33% upside for Passage Bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Raymond James
Chardan Capital
Guggenheim
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Passage Bio
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/05/2024 | PASG | Buy Now | Passage Bio | $1.12 | 1150% | Canaccord Genuity | Whitney Ijem | → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2023 | PASG | Buy Now | Passage Bio | $1.12 | 346.43% | Raymond James | Danielle Brill | $9 → $5 | Maintains | Outperform | Get Alert |
| 08/08/2023 | PASG | Buy Now | Passage Bio | $1.12 | 703.57% | Chardan Capital | Geulah Livshits | $11 → $9 | Maintains | Buy | Get Alert |
| 05/12/2023 | PASG | Buy Now | Passage Bio | $1.12 | 703.57% | Raymond James | Danielle Brill | $10 → $9 | Maintains | Outperform | Get Alert |
| 12/15/2022 | PASG | Buy Now | Passage Bio | $1.12 | 882.14% | Chardan Capital | Geulah Livshits | $18 → $11 | Maintains | Buy | Get Alert |
| 11/11/2022 | PASG | Buy Now | Passage Bio | $1.12 | 882.14% | Guggenheim | Debjit Chattopadhyay | $13 → $11 | Maintains | Buy | Get Alert |
| 11/11/2022 | PASG | Buy Now | Passage Bio | $1.12 | 346.43% | Citigroup | Neena Bitritto-Garg | $7 → $5 | Maintains | Buy | Get Alert |
| 11/08/2022 | PASG | Buy Now | Passage Bio | $1.12 | 614.29% | Canaccord Genuity | Whitney Ijem | → $8 | Initiates | → Buy | Get Alert |
| 05/17/2022 | PASG | Buy Now | Passage Bio | $1.12 | 792.86% | Citigroup | Neena Bitritto-Garg | $15 → $10 | Maintains | Buy | Get Alert |
| 05/17/2022 | PASG | Buy Now | Passage Bio | $1.12 | 792.86% | Raymond James | Danielle Brill | $24 → $10 | Maintains | Outperform | Get Alert |
| 03/08/2022 | PASG | Buy Now | Passage Bio | $1.12 | — | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Neutral | Get Alert |
| 03/04/2022 | PASG | Buy Now | Passage Bio | $1.12 | 2042.86% | Raymond James | Danielle Brill | $29 → $24 | Maintains | Outperform | Get Alert |
| 01/19/2022 | PASG | Buy Now | Passage Bio | $1.12 | 435.71% | Goldman Sachs | Madhu Kumar | $29 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 07/01/2021 | PASG | Buy Now | Passage Bio | $1.12 | 2489.29% | Raymond James | Danielle Brill | — | Initiates | → Outperform | Get Alert |
| 06/15/2021 | PASG | Buy Now | Passage Bio | $1.12 | 2132.14% | BTIG | Yun Zhong | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Passage Bio (PASG)?
The latest price target for Passage Bio (NASDAQ: PASG) was reported by Canaccord Genuity on March 5, 2024. The analyst firm set a price target for $14.00 expecting PASG to rise to within 12 months (a possible 1150.00% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Passage Bio (PASG)?
The latest analyst rating for Passage Bio (NASDAQ: PASG) was provided by Canaccord Genuity, and Passage Bio reiterated their buy rating.
When was the last upgrade for Passage Bio (PASG)?
There is no last upgrade for Passage Bio.
When was the last downgrade for Passage Bio (PASG)?
The last downgrade for Passage Bio Inc happened on March 8, 2022 when JP Morgan changed their price target from N/A to N/A for Passage Bio Inc.
When is the next analyst rating going to be posted or updated for Passage Bio (PASG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on March 5, 2024 so you should expect the next rating to be made available sometime around March 5, 2025.
Is the Analyst Rating Passage Bio (PASG) correct?
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a reiterated with a price target of $0.00 to $14.00. The current price Passage Bio (PASG) is trading at is $1.12, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.